Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMY 101

Drug Profile

AMY 101

Alternative Names: AMY101

Latest Information Update: 20 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Pennsylvania
  • Developer Amyndas Pharmaceuticals
  • Class Anti-inflammatories; Antianaemics; Eye disorder therapies; Peptides; Proteins; Uroprotectives
  • Mechanism of Action Complement C3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Membranous glomerulonephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gingivitis; Periodontitis; SARS-CoV-2 acute respiratory disease
  • Phase I Membranous glomerulonephritis; Paroxysmal nocturnal haemoglobinuria; Renal transplant rejection
  • Discontinued Age-related macular degeneration; Renal failure

Most Recent Events

  • 20 Dec 2022 Amyndas Pharmaceuticals plans a phase II trial for Membranous glomerulonephritis (Amyndas pharmaceuticals pipeline, December 2022)
  • 20 Dec 2022 Amyndas Pharmaceuticals plans a phase II trial for Paroxysmal nocturnal haemoglobinuria (Amyndas Pharmaceuticals pipeline, December 2022)
  • 22 Sep 2022 Discontinued - Phase-I for Age-related macular degeneration (In volunteers) in USA (IV) (Amyndas pipeline, September 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top